Next 10 |
home / stock / zlab / zlab articles
Shares of Duolingo, Inc. (NASDAQ:DUOL) fell sharply during Thursday's session after the company reported first quarter financial results. Duol...
U.S. stocks were mixed, with the Dow Jones gaining around 100 points on Thursday. Shares of Spectrum Brands Holdings, Inc. (NYSE:SPB) rose sharply ...
As of May 9, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in thei...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday. Shares of Archer-Daniels-Midland Company...
Zai Lab Limited (NASDAQ: ZLAB) shares traded lower on Thursday. The stock has pulled back sharply from recent strength. Here's what you need to...
U.S. stocks traded higher, with the Dow Jones index gaining around 200 points on Thursday. Shares of Paychex, Inc. (NASDAQ: PAYX) moved lower durin...
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene thera...
U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. Here are some other big stocks recording losses i...
News, Short Squeeze, Breakout and More Instantly...
Zai Lab Limited Company Name:
ZLAB Stock Symbol:
NASDAQ Market:
Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization China NMPA approval based on comprehensive clinical data demonstrating robust activity of SUL-DUR against carbapenem-resi...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in May and June 2024: J.P. Morgan 20th Annual Global China Summit Panel Discussion: Thursday, May 23, 2024, 10:00...
sBLA submission based on positive results from the ADHERE trial, the first positive global neonatal FC receptor (FcRn) pivotal study for CIDP There are currently no approved therapies available in China for this serious autoimmune disease Milestone underscores Zai Lab’s ope...